Arthur Cohn
Internal Medicine · Sparta, MONPI 1215932488
Payments from drug & device makers
Across 121 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$518
- Neurocrine Biosciences, Inc.$262
- Otsuka America Pharmaceutical, Inc.$194
- Astellas Pharma US Inc$110
- Lilly USA, LLC$88
- Johnson & Johnson$75
- plus $658 from 26 others
What the payments were for
- Food & beverage$1,905100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 35 | $518 |
| Neurocrine Biosciences, Inc. | 13 | $262 |
| Otsuka America Pharmaceutical, Inc. | 12 | $194 |
| Astellas Pharma US Inc | 6 | $110 |
| Lilly USA, LLC | 5 | $88 |
| Johnson & Johnson | 5 | $75 |
| AbbVie | 5 | $69 |
| Indivior Inc. | 3 | $59 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Sumitomo Pharma America, Inc. | 3 | $50 |
| Merck | 3 | $45 |
| AstraZeneca | 3 | $37 |
| Corium, LLC | 3 | $35 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Genentech USA, Inc. | 2 | $30 |
| Mylan Specialty L.p. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Abbott | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Pfizer | 1 | $13 |
| Sun Pharmaceutical Industries Inc. | 1 | $12 |
| Grifols USA, LLC | 1 | $11 |
| Organon | 1 | $10 |
| Ablative Solutions, Inc. | 3 | $0 |
How this compares
$1,905 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 66 | $299,380 |
| Invega SustennaPaliperidone Palmitate | 36 | $130,077 |
| EliquisApixaban | 290 | $89,287 |
| AustedoDeutetrabenazine | 25 | $85,743 |
| Dimethyl Fumarate | 11 | $67,681 |
| RexultiBrexpiprazole | 99 | $66,344 |
| OzempicSemaglutide | 46 | $46,895 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 172 | $38,454 |
| Abilify MaintenaAripiprazole | 12 | $35,784 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 55 | $29,446 |
| XareltoRivaroxaban | 68 | $20,313 |
| JardianceEmpagliflozin | 63 | $19,411 |
| Tiotropium Bromide | 44 | $19,136 |
| JanuviaSitagliptin Phosphate | 61 | $17,192 |
| TrulicityDulaglutide | 17 | $16,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $262 | $299,38066 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $75 | $150,390104 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $194 | $102,128111 claims |
| PfizerEliquis | $13 | $89,287290 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $518 | $85,74325 claims |
| Novo NordiskOzempic | $14 | $46,89546 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $16 | $34,067105 claims |
| Indivior Inc.Suboxone | $59 | $29,44655 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $88 | $23,347244 claims |
| MerckJanuvia | $45 | $17,19261 claims |
| Astellas Pharma US IncMyrbetriq | $110 | $7,13228 claims |
| AstraZenecaSymbicort | $37 | $5,27022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Sparta
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.